Towards optimal treatment for chronic hepatitis C infection

Thesis

Cover

Title page

Contents

Chapter 1: General introduction

Chapter 2: Clinical performance of the new Roche COBAS® TaqMan HCV Test and High Pure System for extraction, detection and quantitation of HCV RNA in plasma and serum

Chapter 3: Prediction of virologic response in diffucult-to-treat chronic hepatitis C patients during high dose interferon induction therapy

Chapter 4: Low level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure

Chapter 5: Early and sustained HCV virological responses to therapy despite suppression of HCV specific T-cells

Chapter 6: High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alfa for chronic hepatitis C virus infection

Chapter 7: Neopterin and ALT as markers of inflammation in chronic hepatitis C patients during administration of the HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa 2a

Chapter 8: Monocyte derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile

Chapter 9: Summary and conclusion

Chapter 10: Samenvatting en conclusie

Dankwoord / acknowledgments

Stellingen